Live
- SC suspends Orissa Cong MLA's sentence in graft case
- RBI lists 6 factors powering India’s take-off to become world’s 3rd largest economy
- Multiple catalysts for re-rating across verticals as RIL exits fourth investment cycle: Morgan Stanley
- ISL announces tentative venue for 2023-24 final
- Indira Gandhi coined 'Gareebi Hatao' slogan, her grandson still repeating it: CM Yogi
- Pawan Kalyan’s assets up by 215 per cent, owns 11 vehicles
- Byju’s vs investors: NCLT defers hearing to June 6
- Biryani blunder: Lord Ram's image on plates sparks outrage in Delhi
- Congress made HD Devegowda PM, don’t know why he is shedding tears: DCM D K Shivakumar
- DGCA Mandates Airlines To Ensure Children under 12 Are Seated with Parents On Flights
Dr Reddy’s ropes in Turkish startup for biosimilar drugs
Dr Reddy’s Laboratories Ltd has inked a strategic collaboration agreement with TR-Pharm, a pharmaceutical startup based in Turkey, for manufacturing and marketing its biosimilar drugs in that country.
TR-Pharm will initially commercialise 3 products of Dr Reddy’s in Turkey
Hyderabad: Dr Reddy’s Laboratories Ltd has inked a strategic collaboration agreement with TR-Pharm, a pharmaceutical startup based in Turkey, for manufacturing and marketing its biosimilar drugs in that country.
Under the agreement, a total of three biosimilar products of Dr Reddy’s will be registered and subsequently commercialised by TR-Pharm in Turkey. The startup, which focuses on the launch of new and innovative medicines, will also manufacture the drug substance and drug products upon completion of its facility.
“Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country,” said Mehmet Goker, General Manager, TR-Pharm.
We are pleased to have already started laying out the groundwork for manufacturing with Dr. Reddy’s for high quality biosimilar products, he added. This collaboration is expected to be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. The company has already begun laying out the groundwork for the technology transfer.
The partnership will also enable Dr Reddy’s to widen the global footprint of its biosimilar business. “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products,” said M V Ramana, Executive Vice President & Head Branded Markets (India and Emerging countries), Dr Reddy’s.
Dr Reddy’s Laboratories is committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey, he added TR Pharm, being a pharma start-up, is focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player.
The company focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA (Middle East and North Africa) regions, besides the local market. It has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.
